Neil McAuslane

Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures—Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder Perceptions

Ting Wang, Neil McAuslane, Lawrence Liberti et al. · Value in Health · 2017 · 43 citations · Full text

Emerging Markets and Emerging Agencies: A Comparative Study of How Key Regulatory Agencies in Asia, Latin America, the Middle East, and Africa are Developing Regulatory Processes and Review Models for New Medicinal Products

Neil McAuslane, Margaret Cone, Jennifer Collins et al. · Drug Information Journal · 2009 · 40 citations

International Regulation, New Medicinal Products, Management +17

A Universal Framework for the Benefit-Risk Assessment of Medicines: Is This the Way Forward?

Stuart Walker, Neil McAuslane, Lawrence Liberti et al. · Therapeutic Innovation & Regulatory Science · 2014 · 35 citations

Drug Safety, Preventive Medicine, Health Policy +13

Is there a need for a universal benefit–risk assessment framework for medicines? Regulatory and industry perspectives

James Leong, Neil McAuslane, Stuart Walker et al. · Pharmacoepidemiology and Drug Safety · 2013 · 31 citations

FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines

Lawrence Liberti, Magda Bujar, Alasdair Breckenridge et al. · Frontiers in Pharmacology · 2017 · 30 citations · Full text